Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Budczies, Jan [VerfasserIn]   i
 Kazdal, Daniel [VerfasserIn]   i
 Menzel, Michael [VerfasserIn]   i
 Beck, Susanne [VerfasserIn]   i
 Kluck, Klaus [VerfasserIn]   i
 Altbürger, Christian [VerfasserIn]   i
 Schwab, Constantin [VerfasserIn]   i
 Allgäuer, Michael [VerfasserIn]   i
 Ahadova, Aysel [VerfasserIn]   i
 Kloor, Matthias [VerfasserIn]   i
 Schirmacher, Peter [VerfasserIn]   i
 Peters, Solange [VerfasserIn]   i
 Krämer, Alwin [VerfasserIn]   i
 Christopoulos, Petros [VerfasserIn]   i
 Stenzinger, Albrecht [VerfasserIn]   i
Titel:Tumour mutational burden
Titelzusatz:clinical utility, challenges and emerging improvements
Verf.angabe:Jan Budczies, Daniel Kazdal, Michael Menzel, Susanne Beck, Klaus Kluck, Christian Altbürger, Constantin Schwab, Michael Allgäuer, Aysel Ahadova, Matthias Kloor, Peter Schirmacher, Solange Peters, Alwin Krämer, Petros Christopoulos & Albrecht Stenzinger
E-Jahr:2024
Jahr:October 2024
Umfang:18 S.
Illustrationen:Illustrationen
Fussnoten:Zuerst veröffentlicht: 27. August 2024 ; Gesehen am 15.10.2024
Titel Quelle:Enthalten in: Nature reviews. Clinical oncology
Ort Quelle:New York, NY : Nature Publ. Group, 2009
Jahr Quelle:2024
Band/Heft Quelle:21(2024), 10 vom: Okt., Seite 725-742
ISSN Quelle:1759-4782
Abstract:Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous mutations present within the cancer genome, varies across and within cancer types. A first wave of retrospective and prospective research identified TMB as a predictive biomarker of response to immune-checkpoint inhibitors and culminated in the disease-agnostic approval of pembrolizumab for patients with TMB-high tumours based on data from the Keynote-158 trial. Although the applicability of outcomes from this trial to all cancer types and the optimal thresholds for TMB are yet to be ascertained, research into TMB is advancing along three principal avenues: enhancement of TMB assessments through rigorous quality control measures within the laboratory process, including the mitigation of confounding factors such as limited panel scope and low tumour purity; refinement of the traditional TMB framework through the incorporation of innovative concepts such as clonal, persistent or HLA-corrected TMB, tumour neoantigen load and mutational signatures; and integration of TMB with established and emerging biomarkers such as PD-L1 expression, microsatellite instability, immune gene expression profiles and the tumour immune contexture. Given its pivotal functions in both the pathogenesis of cancer and the ability of the immune system to recognize tumours, a profound comprehension of the foundational principles and the continued evolution of TMB are of paramount relevance for the field of oncology.
DOI:doi:10.1038/s41571-024-00932-9
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1038/s41571-024-00932-9
 Volltext: https://www.nature.com/articles/s41571-024-00932-9
 DOI: https://doi.org/10.1038/s41571-024-00932-9
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cancer genetics
 Cancer immunotherapy
 Predictive markers
 Tumour biomarkers
K10plus-PPN:1905694660
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69262473   QR-Code
zum Seitenanfang